CLL

Effect of Bruton Tyrosine Kinase Inhibitor on Efficacy of Adjuvanted Recombinant Hepatitis B and Zoster Vaccines

Effect of Bruton Tyrosine Kinase Inhibitor on Efficacy of Adjuvanted Recombinant Hepatitis B and Zoster Vaccines

January 14, 2021

Published in the journal Blood in January 2021, investigators report on the results of an open label phase 2 trial of BTKi on de novo immune responses against Hep B and recall response to RZV in CLL patients who were treatment naive and on therapy with a BTKi. The primary endpoint was serologic response to Hep B-CpG and RZV. The response rate to HepB-CpG was lower in patients on a BTKi (3.8%; 95% CI, 0.7-18.9) than patients who were treatment naive (28.1%; 95% CI, 15.6-45.4; p = .017). In contrast, the response rate to RZV was not different between the BTKi (41.5%; 95% CI, 27.8-56.6) and treatment naive cohorts (59.1%; 95% CI, 38.7-76.7; p = .2). The authors concluded ” BTK inhibitor use was associated with a decreased de novo immune response following HepB-CpG, whereas recall immune response following RZV was not significantly affected by BTKi therapy.”

Reference:

https://ashpublications.org/blood/article/137/2/185/474376/Effect-of-Bruton-tyrosine-kinase-inhibitor-on

en_USEnglish